Mayinglong's subsidiary Mayinglong Meikang received the Drug Registration Certificate for Azelastine Hydrochloride Eye Drops from the National Medical Products Administration on July 10, 2026. The drug, with a specification of 0.05% (6ml:3mg), was approved as a Category 4 chemical drug and is an over-the-counter product (Class A), primarily used to treat eye itching caused by allergic conjunctivitis. The company stated that this approval helps further enrich its ophthalmic product line, but the production and sales of the drug are subject to uncertainties from industry policies and market competition, and reminded investors to be aware of the risks.
Mayinglong Pharmaceutical Group Co LtdSubsidiary obtained drug registration certificate from NMPA for Azelastine Hydrochloride Eye Drops, enabling market entry.